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A B S T R A C T
Phyllodes tumors and fibroadenomas are the most common benign breast tumors. They arise from intralobular fi-
brous tissue as a unique lesion and after a period of time they differentiate in two direction: to fibroadenoma and to
phyllodes tumors. Fibroadenomas grow up to 2–3 cm and then stop growing but phyllodes tumors grow continually and
sometimes are to 40 cm big. Both these lesions have two components, epithelial and stromal. Clinically fibroadenomas
are well circumscibed, hard, oval, movable lesions. They can be solitary, multiple, unilateral and bilateral. They are hor-
mone dependent changes, because they change their own consistency during menstrual cycle and gravidity. The most
commonly used histological classification is in two types: pericanalicular and intracanalicular type. Phyllodes tumors
make about 1% of all breast tumors. This tumor has many synonyms. It starts as fibroadenoma in intralobular stromal
component. It has continuous growth and biologically it can be benign, borderline and malignant. The first description
is from Miller (1838). The main goal is to find the divergence point when the developing is direct to fibroadenoma or
phyllodes tumor. The second goal is to investigate the fate of epithelial and stromal component in these two lesions. Ret-
rospective analysis is made of all fibroadenomas and phyllodes tumors in Pathology Department of Medical Center
»Be`anijska kosa« in the period from 1998 to 2006. In this period, 2919 women were operated for breast changes. 343
fibroadenoma (24, 4%), were diagnosed, benign phyllodes tumor in 95 women (6.7%) and malignant phyllodes in 4 cases
or 0.2%. All slides from these patients were analysed for many different histological parameters and immunohistological
investigation for steroid receptors was also used, c-erbB2 (Her2/Neu), PCNA (proliferative cellular nuclear antigen) and
Ki-67, androgen receptor and p53. All data were statistically investigated (Odds ratio, confidence interval, Fisher exact
test, Wilcoxon sum test and Kendall test). It was concluded that fibroadenomas and phyllodes tumors arise from in-
tralobular fibrous tissue, both changes have very close histology in the beginning and divergent growth starts later. Dif-
ferences are present in stromal component. Phyllodes tumor has two component stroma. Stromal cells in phyllodes tu-
mors are more PCNA positive than in fibroadenomas, also Ki-67 and androgen receptors are more positive in phyllodes
tumors. Histologically phyllodes tumors have perforated capsule with finger like projections. These data determine sur-
gical procedure, wide excision in phyllodes and simple excision in fibroadenomas.
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Introduction
Phyllodes tumors and fibroadenomas are the most
common benign breast tumors. They arise from intralo-
bular fibrous tissue as a unique lesion and after a period of
time they differentiate in two directions: to fibroadenoma
and to phyllodes tumors. Fibroadenomas grow up to 2–3
cm and then stop growing but phyllodes tumors grow con-
tinually and sometimes are to 40 cm big. Both these le-
sions have two components, epithelial and stromal1–3.
Stromal cells are CD34 positive1,2. CD34 positive cells
are called »dendritic interstitial cells«4. According to
Khan3, fibroadenomas are hyperplastic and phyllodes tu-
mors neoplastic lesions.
Clinically fibroadenomas are well circumscribed,
hard, oval, movable lesions. They can be solitary, multi-
ple, unilateral and bilateral6,7. They are hormone de-
pendent changes, because they change own consistency
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during menstrual cycle and gravidity. The most com-
monly used histological classification is in two types:
pericanalicular and intracanalicular (type). This division
has no clinical implication. There are some morphologi-
cal changes in fibroadenomas as: focal stromal multi-
nuclear cells, foci of mature adipose tissue, smooth mus-
cle cells and metaplastic changes. In fibroadenomas we
can sometimes see focal lactation changes, field of fibro-
cystic changes, appocrine changes and multifocal chan-
ges (fibroadenomatoid hyperplasia). Juvenile fibroade-
noma starts earlier but histologically is not different
from usual type. Fibroadenomas bigger than 10–15 cm in
diameter are called giant fibroadenomas. Fibroadenomas
can be multiple and can be associated with breast carci-
nomas. There are no genetic changes in fibroadenomas
and most scientists think that there are no increased
risks for subsequent breast carcinoma8.
Phyllodes tumors makes about 1% of all breast tu-
mors. This tumor has many synonims9. It starts as
fibroadenoma in intralobular stromal component. It has
continuous growth and biologically it can be benign, bor-
derline and malignant. The first description is from
Miller (1838). Tumor phyllodes arise about ten years af-
ter fibroadenomas. The current opinion is that phyllodes
tumors smaller than 4 cm in diameter are benign, be-
tween 4 and 8 cm are borderline, and bigger than 8 cm
are malignant. It has papillary projection on outside sur-
face and this projection can be the reason for recurrence
after surgery. The histological picture is sometimes dif-
ferent from that in fibroadenomas (Figures 2, 3, 4, 5).
There are three biologically different categories: benign
(0–4 mitoses per 10HPF), borderline (5–9 mitoses per
10HPF) and malignant (more than 9 mitoses per 10HPF).
Malignant phyllodes tumors metastasize in lung (66%),
bones (28%), heart (9, 8%) and liver (5, 6%). There are
described metastases also in omentum, stomach, pan-
creas, mesenterium, kidneys, adrenals, and so on.
Therapy depends on histological diagnosis10,11. In fi-
broadenomas, surgical excision is the therapy of choice12.
The cut resection can be close to tumor but in phyllodes
tumor the cut resection has to be about 2 cm away of the
edge of tumor, because some rest of finger like protru-
sions can be the reason of recurrence. In metastases we
can see only stromal cell component and this look like
sarcomatous metastasis13,14.
Material and Methods
The main goal is to find the divergence point when
the developing is direct to fibroadenoma or phyllodes tu-
mor. The second goal is to investigate the fate of epithe-
lial and stromal component in these two lesions.
We made retrospective analysis of all fibroadenomas
and phyllodes tumors in Pathology Department of »Be-
`anijska kosa« Medical Center in the period from 1989 to
2006 (Table 1, Figure 1). In this period, 2919 women
were operated for breast changes. 343 fibroadenomas
were diagnosed (24, 4%), benign phyllodes tumor in 95
women (6, 7%) and malignant phyllodes in 4 cases or 0,2%.
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TABLE 1
THE DISTRIBUTION OF FIBROADENOMAS AND PHYLLODES TUMORS
Frequency Percentage Valid percentage Cumulative percentage
Fibroadenoma pure 30 19.4 19.4 19.4
Fibroadenoma mixed 30 19.4 19.4 38.7
Phyllodes tumours 95 61.3 61.3 100.0
Total 155 100.0 100.0
Fig. 1. The frequency of fibroadenoma and phyllodes tumors.
Fig. 2. (HE, 100x) Mixed picture of fibroadenoma (lower left) and
tumor phyllodes (upper right).
We took 30 fibroadenomas (15 without other prolifera-
tive changes and 15 with some proliferative changes) and
90 phyllodes tumors. All slides from these patients were
analysed for many different histological parameters and
we also used immunohistological investigation for ste-
roid receptors, c-erbB2 (Her2/Neu), PCNA (proliferative
cellular nuclear antigen) and Ki-67, androgen receptor
and p53. All data were statistically investigated (Odds ra-
tio, confidence interval, Fisher exact test, Wilcoxon sum
test and Kendall test).
The mean age of operated women from fibroadenoma
was 31.The youngest patient was seventeen years old
and the oldest 49 years old, SD 10.866.
In the mixed group (fibroadenoma and other proli-
ferative changes), the mean age was 59, 97, the youngest
was 21 years old, the oldest 71 years old with SD 10.788.
The mean age in the group with phyllodes tumor was 32,
the youngest was 14, the oldest 63 and SD was 11.741.
In our series of patients, the mean ages with fibro-
adenoma and phyllodes tumors were very close, 31 and
32. The reasons for this are non-adequate clinical crite-
ria. The mean age of patients in the group with other
proliferative changes was 50.097. The patient was oper-
ated for other reason.
Results
Estrogen receptors
In 63.3% of cases, solitary fibroadenomas were estro-
gen negative, in 16.7% of cases, 30% of fibroadenoma
cells were estrogen positive, in 56.7% mixed fibroade-
noma were estrogen negative, 30% were estrogen posi-
tive. About 42, 5% of phyllodes tumors were estrogen
negative, in 55% of cases, about 30% of cells were estro-
gen positive.
16, 7% of fibroadenomas showed about 30% stromal
cells with estrogen receptors but this precenage in phy-
llodes tumor was present in 55% of cases.
There is no normal distribution according to estrogen
positive cells in all three analyzed groups. (One Sample
Kolmogorov-Smirnov Z=1.962 p=0.001 for solitary fi-
broadenoma, Z=1.777 p=0.004 for mixed fibroadenomas
and Z=1.715 p=0.006 for phyllodes phyllodes tumors.
There is no statistical difference in the number of estro-
gen positive cells in the three analysed groups (Kruskal
Wallis test c2=1.481 p=0.484).
The presence of estrogen receptors in stromal cells
can explain higher proliferative activity as a reason of
bigger growth. Phyllodes tumor accompanies growth of
fibrous component neither in the epithelial component
nor in fibroadenomas.
The receptors for estrogen were analyzed in epithelial
and stromal cells (Figure 6). The positivity in epithelial
cells can be a normal characteristic of these cells. Stro-
mal cells in fibroadenomas are always negative. The
positivity for estrogen receptors in epithelial cells in
fibroadenomas is greater if these cells are hyperplastic.
The positivity of estrogen receptors in epithelial cells
in phyllodes tumors is higher and uniformed in intensity
but in phyllodes tumor we can see the positive reaction in
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Fig. 3. (HE,200x). Two types of stromal cells in tumor phyllodes.
Fig. 4. (HE, 100x). Two cellular components of stroma in phy-
llodes tumor, and fascicle of smooth muscle cells.
Fig. 5. (HE,100x). Perpendicular position o subepi-thelial stroma
cells in phyllodes tumor.
stromal cells, especially in the cells close to ducts. Some-
times around ducts, we can see myoepithelial cells which
are always negative for ER and PR.
Progesteron receptors
In the group of solitary fibroadenomas, progesteron
receptors were negative in 43, 3% vs. mixed fibroade-
noma which were negative in 53,% for PR.
The positivity for PR in phyllodes tumors was higher
than in fibroadenomas which can explain its higher growth
(Figure 7).
There is no normal distribution of progesteron recep-
tor positive cells in all the three analysed groups. (One
Sample Kolmogorov-Smirnov Z=1.582 p=0.013 for soli-
tary fibroadenomas, Z=1.956 p=0.001 for mixed fibro-
adenomas and Z=1.521 p=0.02 for phyllodes tumors.
There is no statistical significance in the number of
progesteron positive cells in all the three group. (Kruskal
Wallis test c2=4.180 p=0.124).
P-53
P-53 was negative in all fibroadenomas and in 82, 5%
of phyllodes tumors. In some cases of phyllodes tumor
the positivity was present in stromal cells15,16.
Ki-67
In 83, 3% of solitary fibroadenomas, Ki-67 was nega-
tive, in the rest of cases, the finding was positive. In 73,
3% of mixed fibroadenomas, Ki-67 was negative and in
30%, it was positive. In 55% of phyllodes tumors, the
finding of Ki 67 was negative, but in the rest of the cases,
the finding was positive.
In cytoplasm of stromal cells in phyllodes tumors,
spotty positivity of Ki 67 was present. The same finding
was in some stromal cells17,18.
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Fig. 6. (ER,100x). Strong positivity in epithelial cells and feeble
in stromal cells.
Fig. 7. (PR,100x). The positive reaction in epitehelial and some
stromal cells.
Fig. 8. The distribution of PCNA positive cells in fibroadenomas,
mixed fibroadenomas and phyllodes tumors.
Fig. 9. (PCNA,200x). Ductal epithelial cells and most of the
stromal cells are positive.
PCNA (Proliferative Cellularnuclear Antigen)
In 10% of solitary fibroadenoma, PCNA was negative,
in 23.3%, there was 5 % of positive cells, in 6.7%, there
was 10% of positive cells, in 36.7%, there was 30% of posi-
tive cells, in 16.7%, there was 50% of positive cells, and in
6.7 %, there was 70 % of positive cells.
In 43.4%, mixed fibroadenoma PCNA was negative,
but in the rest of the cases, it was positive up to 50 %. In
15% of phyllodes tumors, PCNA was negative, in 30%,
there was 5% of positive cells, and in the rest of the cases,
it was positive up to 70%. (Figure 10).
In fibroadenomas and in phyllodes tumors, PCNA
was positive in high percentage (90:85%). This indicates
that both lesion have proliferative potential19.
There is normal distribution of PCNA positive cells in
solitary fibroadenoma (One Sample Kolmogorov Smi-
rnov Z=1.026 p=0.243) (Figure 8), but there is not nor-
mal distribution in mixed fibroadenomas (One Sample
Kolmogorov Smirnov Z=2.024 p=0.01), nor in phyllodes
tumors (One Sample Kolmogorov Smirnov Z=1.674 p=
0.007). There is important difference in the number of
PCNA positive cells in the three analyzed groups (Kru-
skal Wallis test c2=15.0861 p=0.001). There is impor-
tant statistical difference between solitary fibroadenoma
and mixed fibroadenomas (Man Whitney U=219.000 p<
0.001). There is important statistical difference between
mixed fibroadenomas and phyllodes tumors (Man Whit-
ney U=329.500 p=0.001). There is not important statis-
tical difference between solitary fiberoadenomas and phy-
llodes tumors (Man Whitney U=567.000 p=0.686). Soli-
tary fibroadenomas and phyllodes tumors have remark-
able number of PCNA positive cells20.
In very cellular lesions, positive reaction on PCNA is
present in epithelial and stromal cells (Figures 9, 10, 11,
12). This indicates that both components are active and
their cells are normally or intensively divided. In the le-
sions where the growth is stopped, only some epithelial
cells are positive.
Androgen
In 60% of solitary fibroadenomas, androgen was nega-
tive but in the rest of the cases, it was positive up to 50%.
In mixed fibroadenomas, androgen was negative in 76.7%
of the cases, and in the rest, it was positive up to 10%. In
47.5% of phyllodes tumors, androgen was negative, in 37,
55, it was positive up to 20%, and in the rest of the cases,
it was positive up to 30%.
In the cases of phyllodes tumors, androgen was posi-
tive in more than half of the cases, which shows us the
possible influence on proliferation of these cases21–23.
In the normal distribution of the number of andro-
gen, there are not any positive cells in the three investi-
gated groups (One Sample Kolmogorov-Smirnov Z=1.872
p=0.02 for solitary fibroadenomas Z=2.516 p<0.001; for
mixed fibroadenomas and Z=1.955 p=0.01 for phyllodes
tumors).
There is important statistical difference in relation to
androgen positive cells in the three anylised groups (Kru-
skal Wallis test c2=8.678 p=0.013). There is important
statistical difference between solitary and mixed fibro-
adenomas (Man Whitney U=340.500 p=0.049), between
mixed fibroadenomas and phyllodes tumors (Man Whit-
ney U=371.000 p=0.002), but not between solitary fi-
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Fig. 10. (PCNA,200x). There are two types of stromal cells (posi-
tive and negative).
Fig. 11. (PCNA, 100x). Intensive positivity of stromal cells.
Fig. 12. (PCNA, 100x). Intensive positivity of stromal cells.
broadenomas and phyllodes tumors (Man Whitney U=
576.500 p=0.760). More androgen positive cells were
present in solitary fibroadenomas and phyllodes tumors.
Discussion
Fibroadenomas and phyllodes tumors are fibroepi-
thelial tumors which arise from intralobular fibrous ti-
ssue23,24. In the very beginning, both of these tumors are
very similar in composition but histological divergency
starts later21. Fibroadenomas can be solitary or associ-
ated with other breast changes, most commonly with
fibrocystic dysplasia22 or with malignant tumor in the op-
posite breast. The histological criteria are not strong for
small lesions. It is very important to differentiate small
fibroadenomas from fibrous foci in other malignant tu-
mors. In our series, there where 343 fibroademas and 95
phyllodes tumors (343:95 or 11, 8:3, 3%). We divided
fibroadenomas in »pure« group and in mixed group whe-
re they are associated with other proliferative changes.
Quite common association with fibrocystic dysplasia,
adenosis and carcinoma indicates hormonal dysregula-
tion. In fibroadenomas the stromal component, there is
some type of collagenisation or very different types of
metaplasia.The proliferative process can stop when the
lesion grows up to 2–3 cm and the stromal component
also stops with proliferation. In phyllodes tumor, stromal
component continues to grow and some finger like pro-
jections are made. These projections are blamed for re-
current disease24,25. In proliferative stroma in phyllodes
tumors, we can see two types of cells: periductal cells and
the cells located deeper26. Phyllodes tumors can be malig-
nant and they metastasize in lung not in auxiliary lymph
nodes27.There are no cases of fibroadenomas which had
malignant stroma but carcinomas can develop from du-
ctal epithelial cells. We analyzed steroid receptors in
fibroadenomas and phyllodes tumors28. Many investiga-
tors believed that estrogen and progesteron receptors are
important for growth29–32. We also analyzed p53 and
Ki-67 in both lesions. In our cases p53 was negative in all
fibroadenomas and in 80% of phyllodes tumors. In 155 of
phyllodes tumors stromal cells showed p53 expression.
Ki-67 was negative in 80% of fibroadenomas and positive
in 45% of phyllodes tumors. The grade of proliferation
correlates with the growth of changes in the breast33.
PCNA was positive in fibroadenomas and phyllodes tu-
mors. The positivity was greater in phyllodes tumors. In
phyllodes tumors, the positivity of PCNA is present in
stromal cells and in epithelial cells. The presence of
PCNA positivity is in early fibroadenomas and phyllodes
tumor. In later stages, the PCNA positivity is higher in
phyllodes tumors. This explains the continuous growth
of phyllodes tumors. Myoepithelial cells in phyllodes tu-
mors are never positive for PCNA. In phyllodes tumors,
androgen receptors are also positive. Androgen was posi-
tive in myoepithelial and stromal cells.
Conclusions
1. Fibroadenomas and phyllodes tumors arise from in-
tralobular fibrous tissue.
2. In early phases of evolution we can see elements of
both tumors.
3. Fibroadenomas grow up to 2–3 cm and then stop but
phyllodes tumors grow farther.
4. Both tumors have two components, epithelial and fi-
brous.
5. Epithelial cells can be positive for ER, PR and andro-
gen sometimes.
6. Stroma in fibroadenomas is less cellular than in
phyllodes tumors.
7. PCNA and Ki-67 are more often positive in stromal
cells of phyllodes tumors than in fibroadenomas.
8. Expression of androgen receptors is more often in
phyllodes tumors.
9. Evolution of fibroadenoma is directed to calcification
and colagenisation but evolution of phyllodes tumors
is directed to cystic degeneration.
10. Phyllodes tumors can be benign, borderline and ma-
lignant.
11. Fibroadenomas almost never undergo malignant
transformation.
12. Capsule in fibroadenoma is pseudocapsule but in
phyllodes tumors is perforated with fingerlike projec-
tions.
13. All these changes are caused by growth factors.
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FILOIDNI TUMORI I FIBROADENOMI. ISTI PO^ETAK, RAZLI^IT ZAVR[ETAK
S A @ E T A K
Filoidni tumori i fibroadenomi naj~e{}i su benigni tumori dojke. Nastaju od intralobularnoga fibroznog tkiva kao
jedinstvena promjena, a kasnije se diferenciraju u dva smjera: fibroadenom ili filoidni tumor. Fibroadenomi dosti`u
veli~inu 2 do 3 cm i tada obi~no prestaju rasti, a filoidni tumori nastavljaju rasti i mogu dosti}i veli~inu do 40 cm. Obje
lezije sastoje se iz dvije komponente: epitelne i stromalne. Klini~ki fibroadenomi dobro su ograni~ene, ~vrste, ovalne i
pokretne lezije. Mogu biti solitarne, multiple, unilateralne i bilateralne. To su hormonalno ovisne promjene jer mije-
njaju svoju konzistenciju tijekom menstrualnoga ciklusa i trudno}e. Histolo{ki dijele se na dva tipa: perikanalikularni i
intrakanalikularni tip. Filoidni tumori ~ine 1% svih tumara dojke. Ova vrsta tumora ima puno sinonima. Javlja se kao
fibroadenom u intralobularnoj stromalnoj komponenti. Ima kontinuirani rast i biolo{ki se dijeli na benigni, grani~ni i
maligni. Prvi ga je opisao Miler (1838.). Glavni je cilj ovoga rada bio je odrediti to~ku divergencije u tijeku razvoja koja
tumor usmjerava ili k fibroadenomu ili k filoidnom tumoru dojke. Drugi je cilj bio utvrditi ulogu epitelne i stromalne
komponente u ove dvije lezije. Retrospektivnom analizom obuhva}eni su svi fibroadenomi i filoidni tumori Slu`be za
patologiju KBC »Be`anijska kosa« u periodu od 1998. do 2006. godine. U navedenom vremenskom periodu promjene u
dojci operiralo je 2919 `ena, dijagnosticirano je 343 fibroadenoma, 95 benignih filoidnih tumora i 4 maligna filoidna
tumora. Svi uzorci ovih pacijentica analizirani su razli~itim histolo{kim parametrima i obra|eni imunohistokemijski na
stereoidne receptore, c-erbB2(Her2/Neu), PCNA, Ki-67, androgene receptore i p53. Svi podatci statisti~ki su obra|eni.
Zaklju~ak je da fibroadenomi i filoidni tumori nastaju iz intralobularnog fibroznog tkiva. Obje su promjene na po~etku
histolo{ki veoma sli~ne, a divergentni rast javlja se kasnije. Razlike se javljaju u stromalnoj komponenti. Filoidni tumor
ima dvokomponentnu stromu. Stromalne stanice kod filoidnog tumora vi{e su PCNA pozitivne nego kod fibroadenoma,
kao i Ki-67 i androgeni receptori. Histolo{ki filoidni tumori perforiraju kapsulu s »finger like« projekcijama. Ovaj po-
datak zna~ajan je za kirur{ke zahvate jer se zbog toga kod filoidnih tumora radi {iroka ekcizija, a kod fibroadenoma
obi~na ekcizija.
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